

# Commigileadin A: A New Triterpenoid from *Commiphora gileadensis* Aerial Parts

Hossam M. Abdallah<sup>1,2</sup>, Gamal A. Mohamed<sup>1</sup>, Sabrin R. M. Ibrahim<sup>3,4</sup>, Abdulrahman E. Koshak<sup>1</sup>, Ibrahim Alnashri<sup>1</sup>, Abdullah Alghamdi<sup>1</sup>, Abdulghani Aljohani<sup>1</sup>, Abdulrahman Khairy<sup>1</sup>

<sup>1</sup>Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia, <sup>2</sup>Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt, <sup>3</sup>Department of Chemistry, Preparatory Year Program, Batterjee Medical College, Jeddah, Saudi Arabia, <sup>4</sup>Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut, Egypt

Submitted: 17-Mar-2021

Revised: 19-Feb-2022

Accepted: 11-Mar-2022

Published: 07-Jul-2022


## ABSTRACT

**Background:** Genus *Commiphora* (Burseraceae) includes about 150 species of aromatic shrubs located in Africa, India, and the Arabian region. *C. gileadensis* L. has been used for treating several ailments such as constipation, urinary retention, headache, jaundice, joint pain, liver and stomach diseases, and inflammatory disorders. **Objectives:** In this work, a phytochemical investigation of *C. gileadensis* aerial parts was carried out. Moreover, the antimicrobial potential of the new metabolite was assessed. **Materials and Methods:** The aerial parts were extracted at room temperature with methanol (MeOH). The MeOH extract was subjected to various chromatographic techniques to separate the bio-constituents. Their structures were exhaustively specified by utilizing diversified spectroscopic data and comparing them with the literature. The antimicrobial potential of the new compound **1** was assessed toward *Bacillus cereus*, *Escherichia coli*, *Staphylococcus aureus*, and *Clostridium albicans*. **Results:** A new friedelan triterpenoid, commigileadin A [3,11-dioxo-(D: A)-friedeo-lean-27-al] (**1**) and four known metabolites, namely, Stigmasterol (**2**), naringenin (**3**), naringenin-4-methyl ether (**4**), and kaempferol (**5**) were obtained. Compound **1** possessed moderate activity toward *B. cereus* (inhibition zone diameter (IZD): 12.6 mm and minimum inhibitory concentration [MIC]: 8.9 µg/mL) in comparison to ciprofloxacin (IZD: 21.1 mm and MIC: 2.5 µg/mL, respectively). **Conclusion:** This work reported the characterization of a new triterpenoid (**1**) and four known constituents (**2-5**). Compound **1** possessed a moderate activity toward *B. cereus*.

**Key words:** Antimicrobial, Burseraceae, commigileadin, *Commiphora gileadensis*, triterpene

## SUMMARY

- A new friedelan triterpenoid (**1**) and four known constituents (**2-5**) were separated from the aerial parts of *C. gileadensis*. Their structures were characterized by spectral analyses and comparing with the literature. The antimicrobial potential of the new compound **1** was assessed.



**Abbreviations used:** 1D: One dimensional; 2D: Two dimensional; CC: Column chromatography; CDCl<sub>3</sub>: Deuterated chloroform; CHCl<sub>3</sub>: Chloroform; COSY: Correlation spectroscopy; DMSO: Dimethyl sulfoxide; EIMS: Electronimpact mass spectrometry; EtOAc: Ethyl acetate; HMBC: Heteronuclear multiple bond correlation; HRESIMS: Highresolution electrospray ionization mass spectrometry; HSQC: Heteronuclear singlequantum correlation; IR: Infrared; IZD: Inhibition zone diameter; LTQ: Linear trap quadruple; m.p.: Melting point; MeOH: Methanol; MIC: Minimum inhibitory concentration; NMR: Nuclear magnetic resonance; RP: Reversed phase; SiO<sub>2</sub>: Silica gel; TLC: Thinlayer chromatography; UV: Ultraviolet.

## Correspondence:

Prof. Gamal A. Mohamed,  
Department of Natural Products and Alternative  
Medicine, Faculty of Pharmacy, King Abdulaziz  
University, Jeddah - 21589, Saudi Arabia.  
E-mail: gamals2001@yahoo.com  
DOI: 10.4103/pm.pm\_118\_21

## Access this article online

Website: [www.phcog.com](http://www.phcog.com)

## Quick Response Code:



## INTRODUCTION

Genus *Commiphora* (family Burseraceae) includes about 150 species of aromatic shrubs located in Africa, India, and the Arabian region.<sup>[1]</sup> Flora of Saudi Arabia comprises six species of *Commiphora* located mainly in the southwest regions.<sup>[2]</sup> *Commiphora* resin has been used as a fragrance, food additive, and traditional medicine.<sup>[3]</sup> Moreover, its essential oils can be utilized in functional foods and cosmetic and pharmaceutical preparations due to the antioxidant potential in the oil substrates.<sup>[4]</sup> *Commiphora gileadensis* L.<sup>[5]</sup> is a small non-thorny shrub known as an expensive perfume due to its volatile oil constituents. Its shrub gives oleo-gum resin with a nice fragrant odor after removal of the bark or pressing of its stems.<sup>[6]</sup> It is known in Arabic as Ood-e-balsam, Bechan, Balessan, Bisham, Balm of Mecca, or Balsam.<sup>[3]</sup> In Bible, it was given the name “Balm of Gilead” and in Hebrew as “Apharsemon.” It produces a white-to-buff oleo-gum resin characterized by its strong aromatic odor. In traditional Arabian medicine, it is used to

treat constipation, urinary retention, headache, jaundice, joint pain, liver and stomach diseases, and inflammatory disorders, whereas its twigs are used for teeth brushing.<sup>[1]</sup> Externally, the exudate from its bark is utilized for treating skin disorders such as burns, wounds, and infections in Oman and Yemen.<sup>[7,8]</sup> In the Middle East, the aerial parts’ decoction is given as a laxative,

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow\_reprints@wolterskluwer.com

Cite this article as: Abdallah HM, Mohamed GA, Ibrahim SRM, Koshak AE, Alnashri I, Alghamdi A, et al. Commigileadin A: A new triterpenoid from *Commiphora gileadensis* aerial parts. Phcog Mag 2022;18:256-60.

pain reliever, and diuretic.<sup>[5]</sup> It possesses diversified bio-activities such as anti-cancer, anti-hypertensive, anti-inflammatory, hepato-protective, anti-ulcer, antioxidant, anti-diabetic, antiviral, and antibacterial.<sup>[8-12]</sup> Its fresh stem oil contains mainly  $\alpha$ -calacorene, terpinen-4-ol,  $\delta$ -cadinene, viridiflorol, and cadalene.<sup>[11]</sup> The methanol (MeOH) extract of its aerial parts revealed the existence of syringic acid, triterpenoids (oleanonic acid, canophyllal, and friedelin), and flavonols (quercetin and mearnsetin).<sup>[13]</sup> Moreover, chemical investigation of its oleo-gum resin yielded cycloartane triterpenes and eudesmane and guaiane sesquiterpenes that showed cytotoxic activity on prostate cancer cell lines.<sup>[14,15]</sup> Herein, the separation and characterization of one new triterpene, Commigileadin A (**1**) and four known compounds (**2-5**) from *C. gileadensis* aerial parts have been discussed. Moreover, the antimicrobial potential of the new compound was estimated utilizing a disc diffusion assay.

## MATERIALS AND METHODS

### General experimental procedures

Ultraviolet (UV) and infrared (IR) spectroscopy were carried out utilizing the UV-Vis Shimadzu 1601 and Infrared Shimadzu 400 spectrophotometers, respectively. A 9100 Digital Electrothermal Melting Point instrument was utilized to get the melting points. Orbitrap LTQ and JMS-SX/SX 102A JEOL spectrometers were used for electronimpact mass spectrometry (EIMS) and High resolution electrospray ionization mass spectrometry (HRESIMS) measurements, respectively. The optical rotation was carried out utilizing the DIP-370 JASCO polarimeter. BRUKER 850 INOVA was utilized for measuring the NMR spectra. Chromatographic separation was accomplished using SiO<sub>2</sub> 60 and RP-18. Thin-layer chromatography (TLC) analysis was performed using TLC plates (SiO<sub>2</sub> 60 F<sub>254</sub>).

### Plant material

From Al-Baha governorate, *C. gileadensis* aerial parts were collected (May 2017). Dr. Emad Al-Sharif established the plant authentication (Plant Ecology, Biology Department, Faculty of Science and Arts, Khulais, KSA). A Reg. no. CG-0442 specimen was preserved at the Department of Natural Products and Alternative Medicine's herbarium (KAU, Faculty of Pharmacy).

### Extraction and isolation

The powdered *C. gileadensis* aerial parts of (210 g) were extracted at room temperature with methanol (4 × 2 L) using Ultra Turrax. Under reduced pressure, the total MeOH extract was concentrated to produce brown residue (13 g). The residue was slurred with silica gel and partitioned using SiO<sub>2</sub> CC (column chromatography) by CHCl<sub>3</sub>, EtOAc, and MeOH to produce 4.9 g of CHCl<sub>3</sub>, 2.1 g of EtOAc, and 5.4 g of MeOH fractions. The CHCl<sub>3</sub> fraction (4.5 g) was submitted to SiO<sub>2</sub> CC, eluting with gradient *n*-hexane: EtOAc to obtain four subfractions, namely, CGC-1 (75:25), CGC-2 (50:50), CGC-3 (25:75), and CGC-4 (100% EtOAc). Subfraction CGC-2 (960 mg) was separated on SiO<sub>2</sub> CC (*n*-hexane: EtOAc gradient) to get three fractions, namely, CGC-2A to CGC-2C. SiO<sub>2</sub> CC of CGC-2A (204 mg) (*n*-hexane: EtOAc gradient) afforded **1** (10.2 mg). Fraction CGC-2C (191 mg) was treated similarly to CGC-2A to obtain **2** (9 mg). Subfraction CGC-4 (1.19 g) was subjected to SiO<sub>2</sub> CC (*n*-hexane: EtOAc gradient) to produce two fractions CGC-4A and CGC-4B. Fraction CGC-4A (420 mg) was chromatographed on SiO<sub>2</sub> CC (*n*-hexane: EtOAc gradient) to get **3** (22 mg). Similarly, fraction CGC-4B (501 mg) was treated as CGC-4A to obtain **4** (27 mg). SiO<sub>2</sub> CC of the EtOAc fraction (2.0 g) (CHCl<sub>3</sub>:MeOH gradient) afforded four subfractions, namely, CGE-1 (90:10), CGE-2 (75:25), CGE-3 (50:50), and CGE-4 (20:80). Subfraction CGE-1 (240 mg) was chromatographed on SiO<sub>2</sub> CC (gradient CHCl<sub>3</sub>:MeOH) to obtain **5** (14.6 mg of a yellow powder).

### Spectral data

Commigileadin A (**1**): White amorphous powder; m.p. 213–215°C (decompose);  $[\alpha]_D^{20} + 16.8$  (c 0.2, MeOH); IR 2946, 1720, 1707 cm<sup>-1</sup>; NMR spectral data, see Table 1; HRESIMS *m/z* 455.3451 [M + H]<sup>+</sup> (calcd for 455.3447, C<sub>30</sub>H<sub>47</sub>O<sub>3</sub>).

### Antimicrobial activity

The antimicrobial capacities of **1** were assessed toward *Candida albicans*, *Staphylococcus aureus*, *Escherichia coli*, and *Bacillus cereus* as previously stated procedures.<sup>[16-19]</sup> Sterile 6-mm filter paper discs were impregnated with tested compounds (20  $\mu$ L in 5% v/v DMSO) at a concentration of 20  $\mu$ g/disc. Moreover, the minimum inhibitory concentrations (MICs) were determined using a concentration range of 128–1  $\mu$ g/mL. Dimethyl sulfoxide (DMSO) 5% v/v was used as a negative control. Ciprofloxacin and clotrimazole were utilized as antibacterial and antifungal standards, respectively.

## RESULTS AND DISCUSSION

### Isolated metabolite purification

Chemical investigation of the MeOH extract of *C. gileadensis* yielded one new triterpenoidal compound (**1**), along with four known metabolites (**2-5**) [Figure 1]. Their structures were elucidated utilizing

**Table 1:** NMR spectral data of compound 1 (CDCl<sub>3</sub>, 850 and 212.5 MHz)

No.	$\delta_H$ (m, J in Hz)	$\delta_C$	HMBC
1	1.96 m	22.3 CH <sub>2</sub>	3, 5, 10
2	2.39 dd (13.9, 4.3) 2.28 m	41.5 CH <sub>2</sub>	1, 3, 4, 10
3	–	213.1 C	–
4	2.22 q (6.8)	58.2 CH	3, 5, 10, 24
5	–	42.0 C	–
6	1.74 dd (12.8, 5.1) 1.42 m	41.1 CH <sub>2</sub>	7, 8, 10, 24, 25
7	1.36 m 1.32 m	18.1 CH <sub>2</sub>	9
8	1.38 m	52.8 CH	9, 11
9	–	52.0 C	–
10	1.51 m	59.3 CH	1, 2, 4, 5, 11, 24, 25
11	–	213.2 C	–
12	2.25 d (14.5) 2.07 d (14.5)	38.8 CH <sub>2</sub>	13, 14, 18, 27
13	–	47.8 C	–
14	–	37.1 C	–
15	1.21 m 0.96 m	32.3 CH <sub>2</sub>	13
16	1.40 m 1.34 m	33.4 CH <sub>2</sub>	14, 28
17	–	37.7 C	–
18	2.18 dd (12.8, 4.3)	36.5 CH	12, 13, 17, 27, 28
19	1.42 m 1.23 m	35.0 CH <sub>2</sub>	27
20	–	28.4 C	–
21	1.36 m 1.22 m	32.4 CH <sub>2</sub>	17, 29, 30
22	1.45 m	30.6 CH <sub>2</sub>	
23	0.87 d (6.8)	6.8 CH <sub>3</sub>	3, 4, 5
24	0.71 s	14.6 CH <sub>3</sub>	4, 5, 6, 10
25	0.84 s	17.2 CH <sub>3</sub>	8, 9, 10, 11
26	0.67 s	20.0 CH <sub>3</sub>	8, 13, 14, 15
27	9.47 s	209.2 CH	12, 13, 14, 18, 26
28	1.07 s	18.8 CH <sub>3</sub>	17, 18, 22
29	0.98 s	29.4 CH <sub>3</sub>	19, 20, 21, 30
30	0.95 s	34.5 CH <sub>3</sub>	19, 20, 21, 29




Figure 1: Chemical structures of compounds 1-5

one-dimensional (1D) and two-dimensional (2D) nuclear magnetic resonance (NMR), as well as compared with literature data. The known compounds were identified as stigmasterol (2),<sup>[13,20]</sup> naringenin (3),<sup>[21]</sup> naringenin-4-methyl ether (4), (21), and kaempferol (5).<sup>[22]</sup>

### Isolated metabolite characterization

Compound **1** was obtained as a white amorphous powder and possessed a positive Liebermann–Burchard reaction, suggesting its triterpenoidal nature.<sup>[23,24]</sup> It showed a HRESIMS pseudo-molecular peak at  $m/z$  455.3451  $[M + H]^+$  (calcd for 455.3447,  $C_{30}H_{47}O_3$ ), compatible with  $C_{30}H_{46}O_3$  molecular formula. This formula indicates eight unsaturation degrees that are attributed to three carbonyl groups and a five-ring system. The IR displayed absorptions at 2946, 1720, and 1707  $cm^{-1}$ , compatible with the existence of aliphatic C-H as well as aldehyde and ketone carbonyls, respectively. The  $^{13}C$  and  $^1H$  NMR revealed signals for six singlet methyl groups at  $\delta_H$  1.07 (H-28)/ $\delta_C$  18.8 (C-28), 0.67 (H-26)/20.0 (C-26), 0.95 (H-30)/34.5 (C-30), 0.98 (H-29)/29.4 (C-29), 0.84 (H-25)/17.2 (C-25), and 0.71 (H-24)/14.6 (C-24) and a doublet methyl at  $\delta_H$  0.87 (H-23)/ $\delta_C$  6.8 (C-23) [Table 1]. The HMBC cross-peaks of H-28/C-17, C-18, and C-22; H-26/C-8, C-13, C-14, and C-15; H-30/C-19, C-20, C-21, and C-29; H-29/C-19, C-20, C-21, and C-30; H-25/C-8, C-9, C-10, and C-11; H-24/C-4, C-5, C-6, and C-10; and H-23/C-5, C-4, and C-3 established the assignment and location of these methyl groups [Figure 2]. Moreover, the aldehydic proton at  $\delta_H$  9.47 (H-27) and four methine protons at  $\delta_H$  2.22 (H-4), 1.38 (H-8), 1.51 (H-10), and 2.18 (H-18) were noticed. They related to the carbons at  $\delta_C$  209.2, 58.2, 52.8, 59.3, and 36.5, respectively, in heteronuclear singlequantum correlation (HSQC). Their locations were secured based on the noticed heteronuclear multiple bond correlation (HMBC) and  $^1H$ - $^1H$  correlation spectroscopy (COSY) relations [Figure 2]. The  $^1H$  NMR

displayed signals for two methylene groups at  $\delta_H$  2.39 (H-2A) and 2.28 (H-2B) and 2.25 (H-12A) and 2.07 (H-12B). The  $^{13}C$  NMR and HSQC spectra showed 30 carbons; among them, 3 carbonyl carbons at  $\delta_C$  209.2, 213.1, and 213.2 were observed. The NMR data indicated that **1** had friedelan-3,11-dione derivative, carrying an aldehyde group.<sup>[25,26]</sup> The HMBC correlations of the aldehyde proton at  $\delta_H$  9.47 to C-12 ( $\delta_C$  38.8), C-13 (47.8), C-14 (37.1), C-18 (36.5), and C-26 (20.0) confirmed the positioning of the aldehyde group at C-27. Moreover, the NMR of **1** was consistent with those in the literature for kokoonal<sup>[25,27]</sup> with the existence of an extra ketonic group at C-11. The placement of the ketone carbonyls at C-3/C-11 was assured based on the correlations of H-4, H-2, H-1, and H-23 to C-3 ( $\delta_C$  213.1) and H-8, H-10 and H-25 to C-11 carbonyl ( $\delta_C$  213.2) in the HMBC. Based on comparing the  $J$  values and NMR shifts with those in the literature, the relative configuration of **1** was assigned to be the same as that of kokoonal.<sup>[26,27]</sup> From the above evidence, **1** was identified as 3,11-dioxo-(D: A)-friedeo-olean-27-al and named commigileadin A. This name was given to the compound based on the plant's genus and species names.


### Antimicrobial activity

Natural products are a substantial fountainhead of new chemical variety. Many presently accessible antibacterial and antifungal agents have undesired toxicity and their prevalent use has resulted in rapid development of drug-resistant strains, which are the major cause of failure in both agricultural and clinical applications. Thus, the discovery of a novel scaffold for the synthesis and design of new antimicrobial agents for helping in the battle toward pathogenic microorganisms is necessary to overcome the rapidly developed resistance to the existing antimicrobial drugs. It is noteworthy that the MeOH extract of *C. gileadensis* possessed a significant antibacterial potential

**Table 2:** Results of antimicrobial activity of compound 1

Compd	<i>S. aureus</i>		<i>B. cereus</i>		<i>E. coli</i>		<i>C. albicans</i>	
	IZD <sup>c</sup>	MICs <sup>d</sup>	IZD	MICs	IZD	MICs	IZD	MICs
1	9.3±0.19	23.3±1.21	12.6±0.22	8.9±0.11	10.3±0.39	21.1±1.02	7.1±0.09	>100
Cipro. <sup>a</sup>	15.7±0.13	3.7±0.25	21.1±0.29	2.5±0.09	25.1±0.78	3.9±0.18	n.a.	n.a.
Clot. <sup>b</sup>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	17.2±0.13	3.8±0.09

<sup>a</sup>Ciprofloxacin as an antibacterial standard; <sup>b</sup>Clotrimazole as an antifungal standard; <sup>c</sup>IZD, inhibition zone diameter (mm); <sup>d</sup>MICs, minimal inhibitory concentrations (µg/mL); n.a., not applied



toward methicillin-resistant *S. aureus* (MRSA) and *P. aeruginosa*.<sup>[28]</sup> Moreover, it had antimicrobial activity against *Streptococcus salivarius*, *Lactobacillus casei*, *Streptococcus mutans*, *Staphylococcus epidermidis*, and *Fusobacterium nucleatum*.<sup>[6]</sup> Iluz *et al.*<sup>[8]</sup> reported that *C. gileadensis* sap possessed an inhibitory potential toward *Bacillus cereus* and blocked the lectins of *P. aeruginosa* that validate the historical uses of the balsam's sap as an antiseptic agent. Therefore, the antimicrobial potential of the new compound **1** was assessed toward *B. cereus*, *E. coli*, *S. aureus*, and *C. albicans*. The results revealed that **1** had moderate activity toward *B. cereus* (inhibition zone diameter [IZD]: 12.6 mm and MIC: 8.9 µg/mL) compared to ciprofloxacin (IZD: 21.1 mm and MIC: 2.5 µg/mL) and weak activity toward *S. aureus* and *E. coli*, whereas it was inactive toward *C. albicans* [Table 2].

## Acknowledgements

The authors, acknowledge with thanks DSR for technical and financial support.

## Financial support and sponsorship

This project was funded by the Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, under grant no. (G: 119-166-1441).

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Al-Massarany SM, Abbas FA, Demirci B, Baser KH, Khan SI, Al-Rehaily AJ, *et al.* Chemical composition and biological evaluation of the essential oil of *Commiphora opobalsamum* L. *J Herbs Spices Med Plants* 2008;13:111-21.
- Collenette S. *Wildflowers of Saudi Arabia*. Riyadh: National Commission for Wildlife

Conservation and Development (NCWCD); 1999. p. 167.

- Hanuš LO, Řezanka T, Dembitsky VM, Moussaieff A. Myrrh—commiphora chemistry. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2005;149:3-27.
- Assimopoulou A, Zlatanov S, Papageorgiou V. Antioxidant activity of natural resins and bioactive triterpenes in oil substrates. *Food Chem* 2005;92:721-7.
- Dudai N, Shachter A, Satyal P, Setzer WN. Chemical composition and monoterpene enantiomeric distribution of the essential oils from *Commiphora gileadensis*. *Medicines (Basel)* 2017;4:66.
- Al-Sieni AI. The antibacterial activity of traditionally used *Salvadora persica* L. (miswak) and *Commiphora gileadensis* (palsam) in Saudi Arabia. *Afr J Tradit Complement Altern Med* 2014;11:23-7.
- Doa'a Anwar I, Amani S, Alzoreqy A, Al-Dbhani A, Al-Fteih L, Abu-Al-fatah T, *et al.* Therapeutic and preventive effects of *Commiphora gileadensis* against diethylnitrosamine-induced hepatic injury in albino rats. *Afr J Pharm Pharmacol* 2016;10:356-63.
- Iluz D, Hoffman M, Gilboa-Garber N, Amar Z. Medicinal properties of *Commiphora gileadensis*. *Afr J Pharm Pharmacol* 2010;4:516-20.
- Al-Howiriny T, Al-Sohaibani M, Al-Said M, Al-Yahya M, El-Tahir K, Rafatullah S. Hepatoprotective properties of *Commiphora opobalsamum* ("Balessan"), a traditional medicinal plant of Saudi Arabia. *Drugs Exp Clin Res* 2004;30:213-20.
- Al-Howiriny T, Al-Sohaibani M, Al-Said M, Al-Yahya M, El-Tahir K, Rafatullah S. Effect of *Commiphora opobalsamum* (L.) Engl. (Balessan) on experimental gastric ulcers and secretion in rats. *J Ethnopharmacol* 2005;98:287-94.
- Bouslama L, Koudhi B, Alqurashi YM, Chaieb K, Papetti A. Virucidal effect of guggulsterone isolated from *Commiphora gileadensis*. *Planta Med* 2019;85:1225-32.
- El Rabey HA, Al-Sieni AI, Al-Seeni MN, Alsieni MA, Alalawy AI, Almutairi FM. The antioxidant and antidiabetic activity of the Arabian balsam tree "*Commiphora gileadensis*" in hyperlipidaemic male rats. *J Taibah Univ Sci* 2020;14:831-41.
- Abbas FA, Al-Massarany SM, Khan S, Al-Howiriny TA, Mossa JS, Abourashed EA. Phytochemical and biological studies on Saudi *Commiphora opobalsamum* L. *Nat Prod Res* 2007;21:383-91.
- Shen T, Wan W, Yuan H, Kong F, Guo H, Fan P, *et al.* Secondary metabolites from *Commiphora opobalsamum* and their antiproliferative effect on human prostate cancer cells. *Phytochemistry* 2007;68:1331-7.
- Shen T, Yuan H-Q, Wan W-Z, Wang X-L, Wang X-N, Ji M, *et al.* Cycloartane-type triterpenoids from the resinous exudates of *Commiphora opobalsamum*. *J Nat Prod* 2008;71:81-6.
- Ibrahim SR, Abdallah HM, Elkhayat ES, Al Musayeb NM, Asfour HZ, Zayed MF, *et al.* Fusaripeptide A: New antifungal and anti-malarial cyclodepsipeptide from the endophytic fungus *Fusarium* sp. *J Asian Nat Prod Res* 2018;20:75-85.
- Ibrahim SR, Abdallah HM, Mohamed GA, Ross SA. Integracides HJ. New tetracyclic triterpenoids from the endophytic fungus *Fusarium* sp. *Fitoterapia* 2016;112:161-7.
- Ibrahim SR, Mohamed GA, Khayat MT, Al Haidari RA, El-Kholy AA, Zayed MF. A new antifungal aminobenzamide derivative from the endophytic fungus *Fusarium* sp. *Pharmacogn Mag* 2019;15:204-7.
- Mohamed GA, Ibrahim SR, Asfour HZ. Antimicrobial metabolites from the endophytic fungus *Aspergillus versicolor*. *Phytochem Lett* 2020;35:152-5.
- Mohamed GA, Ibrahim SR. Eucalyptone G, a new phloroglucinol derivative and other constituents from *Eucalyptus globulus* labill. *Arkivoc* 2007;15:281-91.
- Wawer I, Zielinska A. <sup>13</sup>C CP/MAS NMR studies of flavonoids. *Magn Reson Chem* 2001;39:374-80.
- Harborne JB. *The Flavonoids: Advances in Research Since 1980*. New Fetter Lane, London, UK, Springer; 2013.
- El-Shanawany M, Sayed H, Ibrahim S, Fayed M. Stigmasterol tetracosanoate, a new stigmasterol ester from the Egyptian *Blepharis ciliaris*. *Drug Res* 2015;65:347-53.

24. Khedr AI, Ibrahim SR, Mohamed GA, Ahmed HE, Ahmad AS, Ramadan MA, *et al.* New ursane triterpenoids from *Ficus pandurata* and their binding affinity for human cannabinoid and opioid receptors. *Arch Pharm Res* 2016;39:897-911.
25. Shehata IA, El-harshany E, Abdallah HM, Esmat A, Abdel-Sattar EA. Anti-inflammatory activity of *Kleinia odora*. *Eur J Integr Med* 2018;23:64-9.
26. Tiam ER, Ngono Bikobo DS, Abouem A Zintchem A, Mbabi Nyemeck N, Moni Ndedi EDF, Betote Diboué PH, *et al.* Secondary metabolites from *Triclisia gillettii* (De Wild) staner (Menispermaceae) with antimycobacterial activity against *Mycobacterium tuberculosis*. *Nat Prod Res* 2019;33:642-50.
27. Giner RM, Gray AI, Gibbons S, Waterman PG. Friedelane triterpenes from the stem bark of *Caloncoba glauca*. *Phytochemistry* 1993;33:237-9.
28. Al-Hazmi AS, Albeshi BM, Alsofyani EM, Alherthi MN, Aljuaid MM, Alfifi OA, *et al.* *In vitro* and *in vivo* Antibacterial effect of *Commiphora gileadensis* Methanolic Extract against Methicillin-Resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa*. *Pak J Biol Sci* 2020;23:1676-80.